Press Releases
Mar 21, 2023
Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

Data shows investigational zolbetuximab plus CAPOX reduced risk of progression or death by 31.3% vs CAPOX alone Study evaluated patients with Claudin 18.2-positive, HER2-negative, locally advanced...

Mar 16, 2023
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer

Pfizer and Astellas announce positive topline results from Phase 3 EMBARK trial NEW YORK and TOKYO, March 16, 2023 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503,...

Mar 13, 2023
Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet

Treatment with fezolinetant resulted in statistically significant reductions in the frequency and severity of VMS and improvements in quality of life TOKYO, March 13, 2023 /PRNewswire/ -- Astellas...

EXPLORE ALL US PRESS RELEASES

Articles
Mar 23, 2023
Judy Kannenberg Named a 2023 Healthcare Businesswomen’s Association Luminary

Astellas congratulates Judy Kannenberg, Vice President, Regulatory Affairs Therapeutic Area Head of Medical Specialties, for being named a 2023 Healthcare Businesswomen’s Association (HBA)...

Sep 20, 2022
Meet our 2022 Working Parents of the Year

Astellas was recently ranked in Seramount’s 2022 list of 100 Best Companies and Best Companies for Dads highlighting our commitment to creating a workplace where working parents are valued and...

Sep 20, 2022
Astellas Consistently Recognized as a Top Company for Working Parents

Astellas ranked again in Seramount’s 2022 “100 Best Companies” list and Best Companies for Dads

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter
Download Fact Sheet

Download Fact Sheet

Sustainability

Sustainability

Investors

Investors

Explore U.S. Products

Explore U.S. Products